Camptothecin

For research use only.

Catalog No.S1288 Synonyms: NSC-100880

54 publications

Camptothecin Chemical Structure

Molecular Weight(MW): 348.35

Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 140 In stock
USD 50 In stock
USD 110 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Camptothecin has been cited by 54 publications

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.
Targets
Topo I [2]
(Cell-free assay)
0.68 μM
In vitro

Camptothecin, a plant alkaloid orignially isolated from Camptotheca acuminate in 1966. [1] Camptothecin is noted to halt cells during the S phase of mitosis. Camptothecin displays nanomolar potency in cytotoxicity against many human tumor cell lines, including HT29, LOX, SKOV3, and SKVLB, with IC50 values ranging from 37 nM to 48 nM. [2] In combination with TNF, Camptothecin induces apoptosis in primary mouse hepatocytes, with an IC50 value of 13 μM. Camptothecin also abrogated the TNF-induced NF-κB Activation, as well as the expression of TNF-receptor associated factor 2 (TRAF2), X-linked inhibitor of apoptosis protein (X-IAP), and FLICE-inhibitory protein (FLIP). [4] In HCT116 cells, Camptothecin (5 μM) induces proteasome-mediated degradation of mixed lineage leukemia 5 (MLL5) protein, which leads to phosphorylation of p53 at Ser392. [5] Due to the low solubility and adverse effects of Camptothecin, various Camptothecin analogues have been developed, and two of them, topotecan and irinotecan, has been approved by FDA and are used in cancer chemotherapy.

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKOV3 MlLqZ5l1d3SxeHnjbZR6KGG|c3H5 NHvXZpdKSzVyPUWxJI5O MXW5NFA{PTJy
SKVLB NWq2bWVH[3m2b4TvfIlkcXS7IHHzd4F6 NHz0fZVKSzVyPUWzJI5O MUe5NFA{PTJy
HT29 MmraZ5l1d3SxeHnjbZR6KGG|c3H5 NXP4cmttUUN3ME24O{45KG6P M4rY[|kxODN3MkC=
KB NXLIc455[3m2b4TvfIlkcXS7IHHzd4F6 NUTHRlN[UUN3ME24JI5O MWe5NFA{PTJy
A427 M13Pdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXP+NUDPxE1? NFT5O|ZFVVOR M{Xle2lEPTB;MkSgcm0> NFe3OFc6QDd4MUGx
PC-3 NF\2dVVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2T0Zp4yKM7:TR?= NUjxfWdQTE2VTx?= NYrkfpg1UUN3ME21O{BvVQ>? MonCPVg4PjFzMR?=
K562adr NXPZ[lV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MU\+NUDPxE1? MofBSG1UVw>? NGjzTmRKSzVyPUW3JI5O M{C5clk5PzZzMUG=
MCF7mdr MlzDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFLrOGx,OSEQvF2= MonwSG1UVw>? MVnJR|UxRTNwMTDuUS=> NFHJT2I6QDd4MUGx
P388 MmjvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUfJR|UxRTN{IH7N NFS4dIEyODN2NkmzNy=>
P388CPT5 R MkPkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFTJTWFKSzVyPUKuPEDPxE1? MnfQNVA{PDZ7M{O=
KBwt MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIDrSYRKSzVyPUSwJI5O MWexNFQyOTR5Nh?=
KBMDR NFPQNYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXXxXmZuUUN3ME23NEBvVQ>? NV;rcoF3OTB2MUG0O|Y>
KBV20C NIqyXlhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWjJRm1XUUN3ME2zNEBvVQ>? NX7QU|Q3OTB2MUG0O|Y>
KB7D NXu2V3U3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGDzXGJKSzVyPUO1JI5O NFLQT40yODRzMUS3Oi=>
KBCamp MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1fzXmlEPTB;MT6wOEDPxE1? MlrsNVA1OTF2N{[=
HT29 Mle1Z5l1d3SxeHnjbZR6KGG|c3H5 M3PkO2lEPTB;OECgcm0> NXm4PFMyOTB6NEG4NFg>
A549 NVHkO4ZP[3m2b4TvfIlkcXS7IHHzd4F6 NHz1Zm9KSzVyPU[3JI5O NX;S[IRZOTB6NEG4NFg>
T24 NVfYZ|Ju[3m2b4TvfIlkcXS7IHHzd4F6 NYTHXFlLUUN3ME24PEBvVQ>? Mn7HNVA5PDF6MEi=
HOP-62 M3LQOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3[xbWlEPTB;MUCgcm0> M4PSNVEyODJyMkiz
HCT-116 NVLDWphKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVzJR|UxRTNyIH7N MYSxNVAzODJ6Mx?=
SF-539 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYjHU41EUUN3ME2xNEBvVQ>? NHj5d4gyOTB{MEK4Ny=>
UACC-62 M3LRdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmDlTWM2OD1zMDDuUS=> M4TKOlEyODJyMkiz
OVCAR-3 MnvpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIfsVmRKSzVyPUKyNEBvVQ>? MYixNVAzODJ6Mx?=
SN12C MmXYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVr6R2NyUUN3ME2yNEBvVQ>? M1\tU|EyODJyMkiz
DU-145 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFiydotKSzVyPUGwJI5O NX\DcYNROTFyMkCyPFM>
MDA-MB-435 M{fJOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWXJR|UxRTRyIH7N MY[xNVAzODJ6Mx?=
WiDr NHewNFZkgXSxdH;4bYNqfHliYYPzZZk> M2Xu[2ROW09? MnW4TWM2OD1zNzDuUS=> MoHLNVE{OzR3Nkm=
A549 M{DCZoN6fG:2b4jpZ4l1gSCjc4PhfS=> NFzxcWNFVVOR NWPBW4tpUUN3ME2xOEBvVQ>? MkXBNVE{OzR3Nkm=
MKN45 MkDuZ5l1d3SxeHnjbZR6KGG|c3H5 M2LiZmROW09? M3TPTmlEPTB;MUegcm0> NVTEOJdHOTF|M{S1Olk>
SK-OV-3 M{\peIN6fG:2b4jpZ4l1gSCjc4PhfS=> M2qxbGROW09? MUHJR|UxRTJyIH7N NVPZUGF[OTF|M{S1Olk>
H128 MkPwZ5l1d3SxeHnjbZR6KGG|c3H5 M{DEZmROW09? MXPJR|UxRTF6IH7N MV:xNVM{PDV4OR?=
SK-BR-3 NW[4WJFb[3m2b4TvfIlkcXS7IHHzd4F6 NGT4TIFFVVOR NIT3fY9KSzVyPUKwJI5O M2ToO|EyOzN2NU[5
LX-1 M3\yNIN6fG:2b4jpZ4l1gSCjc4PhfS=> NFLpflFFVVOR NFfTZ|BKSzVyPUGyNEBvVQ>? M2DjfVEyQDV6N{O3
HCT116 NF;tUlRkgXSxdH;4bYNqfHliYYPzZZk> M{LUWGROW09? M33ScGlEPTB;OTDuUS=> M4TXS|EyQDV6N{O3
A2780 MY\jfZRwfG:6aXPpeJkh[XO|YYm= M2fsNGROW09? NWe3XFh1UUN3ME20JI5O M{fzNlEyQDV6N{O3
IMR-32 Mni0Z5l1d3SxeHnjbZR6KGG|c3H5 NEjHZVd,OTBizszN MlTRSG1UVw>? MWXJR|UxRTJwMkGgcm0> MX2xNlYyPzh7NB?=
P388 MmrSZ5l1d3SxeHnjbZR6KGG|c3H5 M1m0UGlEPTB;MUOgcm0> MVyxNlYzODB6MR?=
Lewis NEm2fYxkgXSxdH;4bYNqfHliYYPzZZk> M3jXOGlEPTB;M{Ogcm0> MUSxNlYzODB6MR?=
JLC MVrjfZRwfG:6aXPpeJkh[XO|YYm= MlG1TWM2OD13Lk[gcm0> NEW2THkyOjZ{MEC4NS=>
HT-29 NHL0XotkgXSxdH;4bYNqfHliYYPzZZk> MVLJR|UxRTFwNDFOwG0> NXXj[oRlOTJ4M{m1OFE>
Caki-2 MX\jfZRwfG:6aXPpeJkh[XO|YYm= MXTJR|UxRTNwOU[g{txO NWe0WlZ7OTJ4M{m1OFE>
A549 NIHIdXdkgXSxdH;4bYNqfHliYYPzZZk> MXjJR|UxRTJwNUOg{txO M1PUSVEzPjN7NUSx
HEC-1-B NVrFRWZ4[3m2b4TvfIlkcXS7IHHzd4F6 MojLTWM2OD16Lk[0JO69VQ>? MkfHNVI3Ozl3NEG=
HL-60 NGLEWolkgXSxdH;4bYNqfHliYYPzZZk> NGnwcFlKSzVyPU[2JI5O MWCxNlY{QTV2MR?=
Col2 NIW5S4NkgXSxdH;4bYNqfHliYYPzZZk> Ml64glEh|ryP MmfWSWQ2OD13NzDuUS=> M3q1cVE2ODR|NEC3
HUVEC MlTSZ5l1d3SxeHnjbZR6KGG|c3H5 MYH+NUDPxE1? MXTFSFUxRTJ3ODDuUS=> MWqxOVA1OzRyNx?=
KB MWHjfZRwfG:6aXPpeJkh[XO|YYm= MX7+NUDPxE1? NEXGSo1GTDVyPUKyJI5O MVqxOVA1OzRyNx?=
LCNaP NWO0[ol1[3m2b4TvfIlkcXS7IHHzd4F6 NWLobXRDhjFizszN M2rXXmVFPTB;Mkigcm0> MWixOVA1OzRyNx?=
Lu1 NGfzRZZkgXSxdH;4bYNqfHliYYPzZZk> NFHPdXd,OSEQvF2= M1rQWmVFPTB;Mkmgcm0> MXexOVA1OzRyNx?=
RPMI8402 M{TodoN6fG:2b4jpZ4l1gSCjc4PhfS=> NIO3SZJ,OTBizszN NIn5T45KSzVyPU[gcm0> NIToVJUyPTR6MkmyPS=>
CPT-K5 M3S0RYN6fG:2b4jpZ4l1gSCjc4PhfS=> NYnNTVUyhjFyIN88US=> MU\JR|UxRjFyIN88US=> MlfSNVU1QDJ7Mkm=
P388 MXPjfZRwfG:6aXPpeJkh[XO|YYm= M{HGdp4yOCEQvF2= M1;kXmlEPTB;MUSgcm0> NV3CRoI5OTV2OEK5Nlk>
P388/CPT45 NHvVfo9kgXSxdH;4bYNqfHliYYPzZZk> NHvDfZp,OTBizszN M{DBTGlEPTB-MUCg{txO MnPDNVU1QDJ7Mkm=
KB3-1 Mk\GZ5l1d3SxeHnjbZR6KGG|c3H5 NWLNd3d5hjFyIN88US=> NH7kVIVKSzVyPUSwJI5O NWr5V3A{OTV2OEK5Nlk>
KBV-1 + MDR1 NWLiWIt5[3m2b4TvfIlkcXS7IHHzd4F6 M3rZWJ4yOCEQvF2= M4PKWGlEPTB;NESwJI5O MUSxOVQ5Ojl{OR?=
KBH NF;QUnVkgXSxdH;4bYNqfHliYYPzZZk> NVzzU2t3hjFyIN88US=> MXjJR|UxRTR2MDDuUS=> MnzZNVU1QDJ7Mkm=
HOP-62 M{DTfYN6fG:2b4jpZ4l1gSCjc4PhfS=> M1;Pep4yOCEQvF2= NVn6b|U{T0l3ME2xNEBvVQ>? M2\xSlE2PTB7MU[0
HCT-116 NIKxUHFkgXSxdH;4bYNqfHliYYPzZZk> MoPJglExKM7:TR?= NH[3dZJIUTVyPUOwJI5O NFT4OIoyPTVyOUG2OC=>
F-539 NUTWc|cz[3m2b4TvfIlkcXS7IHHzd4F6 NXfn[ndHhjFyIN88US=> NVroPIkzT0l3ME2xNEBvVQ>? M{fwWFE2PTB7MU[0
UACC-62 MYfjfZRwfG:6aXPpeJkh[XO|YYm= MoHWglExKM7:TR?= NVrzN2NxT0l3ME2xNEBvVQ>? NYj1ZWE2OTV3MEmxOlQ>
OVCAR-3 M1jLe4N6fG:2b4jpZ4l1gSCjc4PhfS=> M2rMfp4yOCEQvF2= NWPt[pVjT0l3ME2yNlAhdk1? MmHvNVU2ODlzNkS=
SN12C MmDYZ5l1d3SxeHnjbZR6KGG|c3H5 NVnzSFhXhjFyIN88US=> M2KzVGdKPTB;MkCgcm0> MVGxOVUxQTF4NB?=
DU-145 MmfkZ5l1d3SxeHnjbZR6KGG|c3H5 NHvhOoR,OTBizszN NX\1RmVPT0l3ME2xNEBvVQ>? NGLJb4cyPTVyOUG2OC=>
MDA-MB-435 MWTjfZRwfG:6aXPpeJkh[XO|YYm= MlXwglExKM7:TR?= NHTlT|FIUTVyPUSwJI5O M1LwU|E2PTB7MU[0
MT-4 NXX2T444[3m2b4TvfIlkcXS7IHHzd4F6 NVzw[W1XUUN3ME20JI5O MWmxO|I2PDZ4OR?=
CCRF-CEMc MlG4Z5l1d3SxeHnjbZR6KGG|c3H5 NET1R41KSzVyPUOgcm0> NXnzfmZSOTd{NUS2Olk>
WIL-2NSd NIDFfIJkgXSxdH;4bYNqfHliYYPzZZk> Mn74TWM2OD13IH7N NILGbXoyPzJ3NE[2PS=>
CCRF-SB M320c4N6fG:2b4jpZ4l1gSCjc4PhfS=> MYrJR|UxRTNibl2= MlzCNVczPTR4Nkm=
CRL 7065 NX3QfZZX[3m2b4TvfIlkcXS7IHHzd4F6 NEfVR2FKSzVyPUSwNEBvVQ>? M2DLUFE4OjV2Nk[5
SK-MEL-28b MVLjfZRwfG:6aXPpeJkh[XO|YYm= M2faUmlEPTB;NECgcm0> NV3kOoJGOTd{NUS2Olk>
MCF-7 NGG3ZmVkgXSxdH;4bYNqfHliYYPzZZk> NWTkSlJ[UUN3ME20NEBvVQ>? MWGxO|I2PDZ4OR?=
SKMES-1 M{G1OIN6fG:2b4jpZ4l1gSCjc4PhfS=> NHjNdZZKSzVyPUGwJI5O NYS5W4t[OTd{NUS2Olk>
HepG2 NYq4OHlJ[3m2b4TvfIlkcXS7IHHzd4F6 NF3hdJpKSzVyPUOwJI5O NX:5NVcyOTd{NUS2Olk>
DU145 MmLJZ5l1d3SxeHnjbZR6KGG|c3H5 Mle1TWM2OD1zMDDuUS=> MlPnNVczPTR4Nkm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin1 / CDK1 / CDK2 ; 

PubMed: 29963130     


Western blot analysis indicated that camptothecin (6 µM) downregulates the expression of cell-cycle-associated proteins, cyclin 1, CDK1 and CDK2 in NPC cells. β-actin was used as a loading control.

Vimentin / Fibronectin / E-cadherin ; 

PubMed: 29963130     


Western blot analysis revealed that camptothecin (6 µM) treatment downregulates the expression of vimentin and fibronectin, and upregulates the expression of E-cadherin in NPC cells. β-actin was used as a loading control. NPC, nasopharyngeal carcinoma.

TGF-β / PI3K / pPI3K / AKT / pAKT ; 

PubMed: 29963130     


Western blot analysis revealed that camptothecin (6 µM) treatment inhibits the expression of TGF-β, PI3K and AKT in NPC cells. 

p53 / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 17548347     


NPCs in trophic factor-containing media were treated with 10 μM camptothecin for 0, 2, 4, 6, or 8 h, and extracts were immunoblotted for p53, active cleaved caspase-3, cleaved PARP, and total GSK3α/β as a loading control.

29963130 17548347
In vivo Camptothecin (8 mg/kg) displays complete growth inhibition and regression in mice xenografts of various tumors, including colon, lung, breast, stomach, and ovary tumors. [3] In mice, combinations of Camptothecin (50 mg/kg) and TNF (5 and 7 μg/kg), but not Camptothecin alone, induces liver damage. [4]

Protocol

Kinase Assay:[2]
- Collapse

Topoisomerase I Cleavable Complex Assay:

Topoisomerase I is isolated from calf thymus and is devoid of topoisomerase II. All reactions are carried out in 10 mL volumes of reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.5 mM EDTA, and 30 pg/mL BSA) in microtiter plates. Camptothecin is dissolved in DMSO at 10 mg/mL and serially diluted in 96-well microtiter plates to which the 32P end-labeled pBR322 DNA and topoisomerase enzyme are added. The reaction mixture is incubated at room temperature for 30 min and then the reaction stopped by adding 2 mL of a mixture of sodium dodecyl sulfate and proteinase K (1.6% and 0.14 mg/mL final concentrations, respectively). The plates are heated at 50 °C for 30 min, 10 mL of standard stop mixture containing 0.45 N NaOH is added in order to generate single-stranded DNA, and the samples are electrophoresed in 1.5% agarose gels in TBE buffer. Gels are blotted on nitrocellulose paper, dried, and exposed to X-ray film. The units of cleavage are calculated from the autoradiographs and plotted against the log drug concentration. The IC50 values are then obtaine
Cell Research:[2]
- Collapse
  • Cell lines: U87MG, A549 and H838 cells
  • Concentrations: 0.17 nM–10 mM
  • Incubation Time: 48 hours
  • Method: Tumor cells are plated in 100 μL of medium in 96-well microtiter plates at a density of 1500 to 4000 cells per well and allowed to adhere overnight. Cells are incubated with Camptothecin for 48 hours and then with fresh medium for 48 hours. Camptothecin at each concentration is added in quadruplicate. Following a 4-hour incubation of treated cells with MTT, the reduced dye product is extracted from the cells with 0.2 mL of DMSO followed by 50 μL of Sorensen's buffer. The plates are shaken briefly, and the absorbance at 570 nm is read and quantitated. Curves are fitted to the MTT assay data using a four-parameter logistic equation.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Nude mice (NIH-I high fertility strain) bearing xenografts of CASE, SW48, DOY, SPA, and CLO cells
  • Dosages: 0–8 mg/kg
  • Administration: Administered via i.m. or i.v. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (8.61 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 348.35
Formula

C20H16N2O4

CAS No. 7689-03-4
Storage powder
in solvent
Synonyms NSC-100880
Smiles CCC1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC=CC5=C4)C2=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Camptothecin | Camptothecin supplier | purchase Camptothecin | Camptothecin cost | Camptothecin manufacturer | order Camptothecin | Camptothecin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID